Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Eledon Pharmaceuticals, Inc.ELDN · Entity 6160 | Director | January 10, 2026 | January 16, 2026 |
| Tenaya Therapeutics, Inc.TNYA · Entity 6506 | Director | May 28, 2026 | May 29, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Eledon Pharmaceuticals, Inc.
Report date January 10, 2026 · Filed January 16, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,430 |
Reported balance
After 2026-01-10 transaction · row 1
1 source rowRow 1 · 2026-01-10 · Exercise / conversion · Acquired 3,430 · Balance 3,430 F1: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-01-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-01-10 · Exercise / conversion · Disposed 3,430 · Balance 0 F1: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026.
Tenaya Therapeutics, Inc.
Report date May 28, 2026 · Filed May 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.80 · Expires 2036-05-27 | Direct | 120,000 |
Reported balance
After 2026-05-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-28 · Grant · Acquired 120,000 · Balance 120,000 F1: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CinCor Pharma, Inc.
Report date February 24, 2023 · Filed February 24, 2023
Section 16 reporting ended · disclosed 2023-02-24. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2032-01-10 | Direct | 0 |
Reported balance
After 2023-02-24 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-02-24 · Disposition to issuer · Disposed 47,954 · Balance 0 F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price less than $26.00 per share (the "Cash Amount") was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive, without interest, (i) cash in an amount equal to the product of (1) the total number of Shares subject to such option as of immediately prior to the effective time of the merger multiplied by (2) the excess of the Cash Amount over the exercise price payable per Share under such option, and (ii) one contingent value right per Share subject to such option, representing the right to receive a contingent payment of $10.00 per share, in cash, upon the achievement of a specified milestone by December 31, 2033. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger").
F2: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price less than $26.00 per share (the "Cash Amount") was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive, without interest, (i) cash in an amount equal to the product of (1) the total number of Shares subject to such option as of immediately prior to the effective time of the merger multiplied by (2) the excess of the Cash Amount over the exercise price payable per Share under such option, and (ii) one contingent value right per Share subject to such option, representing the right to receive a contingent payment of $10.00 per share, in cash, upon the achievement of a specified milestone by December 31, 2033.
MyoKardia, Inc.
Report date May 02, 2018 · Filed October 29, 2019
Section 16 reporting ended · disclosed 2019-10-29. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 22,157 |
Ending reported balance
After 2019-02-25 transaction · row 11
11 source rows · reconciled sequenceRow 1 · 2018-05-02 · Exercise / conversion · Acquired 5,457 · Balance 9,610 Row 2 · 2018-05-09 · Exercise / conversion · Acquired 4,500 · Balance 14,110 Row 3 · 2018-05-31 · Exercise / conversion · Acquired 364 · Balance 14,474 Row 4 · 2018-07-10 · Exercise / conversion · Acquired 364 · Balance 14,838 Row 5 · 2018-08-09 · Exercise / conversion · Acquired 363 · Balance 15,201 Row 6 · 2018-09-04 · Exercise / conversion · Acquired 364 · Balance 15,565 Row 7 · 2018-10-01 · Exercise / conversion · Acquired 364 · Balance 15,929 Row 8 · 2018-10-11 · Exercise / conversion · Acquired 2,500 · Balance 18,429 Row 9 · 2018-11-06 · Exercise / conversion · Acquired 364 · Balance 18,793 Row 10 · 2018-12-03 · Exercise / conversion · Acquired 364 · Balance 19,157 Row 11 · 2019-02-25 · Exercise / conversion · Acquired 3,000 · Balance 22,157 |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.95 · Expires 2027-01-31 | Direct | 110,160 |
Reported balance
After 2018-05-02 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2018-05-02 · Exercise / conversion · Disposed 5,457 · Balance 110,160 F1: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.95 · Expires 2027-01-31 | Direct | 105,660 |
Reported balance
After 2018-05-09 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2018-05-09 · Exercise / conversion · Disposed 4,500 · Balance 105,660 F1: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.95 · Expires 2027-01-31 | Direct | 105,296 |
Reported balance
After 2018-05-31 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2018-05-31 · Exercise / conversion · Disposed 364 · Balance 105,296 F1: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.95 · Expires 2027-01-31 | Direct | 104,932 |
Reported balance
After 2018-07-10 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2018-07-10 · Exercise / conversion · Disposed 364 · Balance 104,932 F1: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.95 · Expires 2027-01-31 | Direct | 104,569 |
Reported balance
After 2018-08-09 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2018-08-09 · Exercise / conversion · Disposed 363 · Balance 104,569 F1: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.95 · Expires 2027-01-31 | Direct | 104,205 |
Reported balance
After 2018-09-04 transaction · row 17
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 17 · 2018-09-04 · Exercise / conversion · Disposed 364 · Balance 104,205 F1: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.95 · Expires 2027-01-31 | Direct | 103,841 |
Reported balance
After 2018-10-01 transaction · row 18
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 18 · 2018-10-01 · Exercise / conversion · Disposed 364 · Balance 103,841 F1: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.95 · Expires 2027-01-31 | Direct | 101,341 |
Reported balance
After 2018-10-11 transaction · row 19
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 19 · 2018-10-11 · Exercise / conversion · Disposed 2,500 · Balance 101,341 F1: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.95 · Expires 2027-01-31 | Direct | 100,977 |
Reported balance
After 2018-11-06 transaction · row 20
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 20 · 2018-11-06 · Exercise / conversion · Disposed 364 · Balance 100,977 F1: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.95 · Expires 2027-01-31 | Direct | 100,613 |
Reported balance
After 2018-12-03 transaction · row 21
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 21 · 2018-12-03 · Exercise / conversion · Disposed 364 · Balance 100,613 F1: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.95 · Expires 2027-01-31 | Direct | 3,250 |
Reported balance
After 2019-02-25 transaction · row 22
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 22 · 2019-02-25 · Exercise / conversion · Disposed 3,000 · Balance 3,250 F2: On February 1, 2017, the Reporting Person was granted an option to purchase 25,000 shares of Common Stock under the issuer's 2015 Equity Incentive Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the issuer's securities. On June 28, 2018, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 6,250 of the shares underlying such option. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date.
F2: On February 1, 2017, the Reporting Person was granted an option to purchase 25,000 shares of Common Stock under the issuer's 2015 Equity Incentive Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the issuer's securities. On June 28, 2018, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 6,250 of the shares underlying such option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 28, 2026 Filed May 29, 2026 23:08 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 120,000 | $0.00 Strike: $0.80 | $0.00 |
DisclosureSEC source: 0001193125-26-249113 · ownership.xml · derivative · entry 1 Lee June · CIK 0001696493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,000 Underlying: Common Stock · 120,000 shares Expires 2036-05-27 F1 · derivative.exercise_date: Option granted pursuant to the Amended and Restated Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 28, 2027, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| January 10, 2026 Filed Jan 16, 2026 22:00 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | Exercise / conversionRestricted Stock Units · Derivative | 3,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-015485 · ownership.xml · derivative · entry 2 Lee June · CIK 0001696493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,430 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026. F1 · derivative.exercise_date: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026. F1 · derivative.expiration_date: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026. Read SEC document |
| January 10, 2026 Filed Jan 16, 2026 22:00 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | Exercise / conversionCommon Stock | 3,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-015485 · ownership.xml · nonDerivative · entry 1 Lee June · CIK 0001696493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,430 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares issuable on settlement of restricted stock units ("RSUs") for common stock on a one-for-one basis granted to the reporting person. The RSUs were issued on January 10, 2025 and vested 100% on January 10, 2026. Read SEC document |
| May 29, 2025 Filed May 30, 2025 22:50 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 107,400 | $0.00 Strike: $0.44 | $0.00 |
DisclosureSEC source: 0000950170-25-079943 · ownership.xml · derivative · entry 1 Lee June · CIK 0001696493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,400 Underlying: Common Stock · 107,400 shares Expires 2035-05-28 F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 29, 2026, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 22:30 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantRestricted Stock Units · Derivative | 3,430 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-004915 · ownership.xml · derivative · entry 2 Lee June · CIK 0001696493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,430 Underlying: Common Stock · 3,430 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's common stock upon settlement for no consideration. F3 · derivative.exercise_date: 100% of the total restricted stock units will vest on January 10, 2026. F3 · derivative.expiration_date: 100% of the total restricted stock units will vest on January 10, 2026. Read SEC document |
| January 10, 2025 Filed Jan 13, 2025 22:30 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 30,870 | $0.00 Strike: $4.04 | $0.00 |
DisclosureSEC source: 0000950170-25-004915 · ownership.xml · derivative · entry 1 Lee June · CIK 0001696493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,870 Underlying: Common Stock · 30,870 shares Expires 2035-01-10 F1 · derivative.exercise_date: This option represents a right to purchase up to 30,870 shares of common stock, which option vests with respect to 100% of the total number of shares on January 10, 2026. Read SEC document |
| October 18, 2024 Filed Oct 22, 2024 00:38 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 34,000 | $0.00 Strike: $2.04 | $0.00 |
DisclosureSEC source: 0000950170-24-116060 · ownership.xml · derivative · entry 1 Lee June · CIK 0001696493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2034-10-17 F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full May 31, 2025, or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 00:17 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 29,532 | $0.00 Strike: $7.12 | $0.00 |
DisclosureSEC source: 0001209191-23-036510 · doc4.xml · derivative · entry 1 Lee June · CIK 0001696493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,532 Underlying: Common Stock · 29,532 shares Expires 2033-06-08 F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full upon the first anniversary of the date of grant or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| May 01, 2023 Filed May 2, 2023 22:43 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 150,437 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001209191-23-026724 · doc4.xml · derivative · entry 1 Lee June · CIK 0001696493 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,437 Underlying: Common Stock · 150,437 shares Expires 2033-05-01 F1 · derivative.exercise_date: This option represents a right to purchase up to 150,437 shares of Common Stock, which option vests with respect to 75,219 shares on May 1, 2024 and with respect to 75,218 shares on May 1, 2025. Read SEC document |
| February 24, 2023 Filed Feb 24, 2023 23:37 UTC | CinCor Pharma, Inc. CINC · Entity 116342 | Disposition to issuerStock Option (Right to Buy) · Derivative | 47,954 | Not disclosed Strike: $16.00 | Not disclosed |
DisclosureSEC source: 0001209191-23-012893 · doc4.xml · derivative · entry 1 Lee June · CIK 0001696493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,954 shares Expires 2032-01-10 F1 · kind: Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 8, 2023, by and among CinCor Pharma, Inc. (the "Issuer"), AstraZeneca Finance and Holdings Inc. ("Parent") and Cinnamon Acquisition, Inc., a wholly owned subsidiary of Parent ("Purchaser"), on February 24, 2023, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). F2 · price: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price less than $26.00 per share (the "Cash Amount") was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive, without interest, (i) cash in an amount equal to the product of (1) the total number of Shares subject to such option as of immediately prior to the effective time of the merger multiplied by (2) the excess of the Cash Amount over the exercise price payable per Share under such option, and (ii) one contingent value right per Share subject to such option, representing the right to receive a contingent payment of $10.00 per share, in cash, upon the achievement of a specified milestone by December 31, 2033. F2 · derivative.exercise_date: At the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option with an exercise price less than $26.00 per share (the "Cash Amount") was accelerated and became fully vested and exercisable and was cancelled and automatically converted into the right to receive, without interest, (i) cash in an amount equal to the product of (1) the total number of Shares subject to such option as of immediately prior to the effective time of the merger multiplied by (2) the excess of the Cash Amount over the exercise price payable per Share under such option, and (ii) one contingent value right per Share subject to such option, representing the right to receive a contingent payment of $10.00 per share, in cash, upon the achievement of a specified milestone by December 31, 2033. Read SEC document |
| February 01, 2023 Filed Feb 2, 2023 23:05 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.08 | $0.00 |
DisclosureSEC source: 0001209191-23-006345 · doc4.xml · derivative · entry 1 Lee June · CIK 0001696493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-02-01 F1 · derivative.exercise_date: This option represents a right to purchase up to 20,000 shares of Common Stock, which option vests with respect to 100% of the total number of shares on 2/1/2024. Read SEC document |
| June 10, 2022 Filed Jun 14, 2022 00:56 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to buy) · Derivative | 39,727 | $0.00 Strike: $5.26 | $0.00 |
DisclosureSEC source: 0001209191-22-036531 · doc4.xml · derivative · entry 1 Lee June · CIK 0001696493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,727 Underlying: Common Stock · 39,727 shares Expires 2032-06-09 F1 · derivative.exercise_date: Option granted pursuant to the Tenaya Therapeutics, Inc. 2021 Equity Incentive Plan. Option will vest in full upon the first anniversary of the date of grant or, if earlier, the day immediately before the date of the next annual meeting of stockholders that occurs after the grant date, subject to the Reporting Person continuing to be a service provider to the Issuer through each applicable vesting date. Read SEC document |
| February 01, 2022 Filed Feb 2, 2022 22:32 UTC | Eledon Pharmaceuticals, Inc. ELDN · Entity 6160 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $3.97 | $0.00 |
DisclosureSEC source: 0001209191-22-006471 · doc4.xml · derivative · entry 1 Lee June · CIK 0001696493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-02-01 F1 · derivative.exercise_date: This option represents a right to purchase up to 20,000 shares of Common Stock, which option vests with respect to 100% of the total number of shares on 2/1/2023. Read SEC document |
| January 06, 2022 Filed Jan 10, 2022 21:15 UTC | CinCor Pharma, Inc. CINC · Entity 116342 | GrantStock Option (Right to Buy) · Derivative | 47,954 | $0.00 Strike: $16.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002684 · doc4.xml · derivative · entry 1 Lee June · CIK 0001696493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,954 Underlying: Common Stock · 47,954 shares Expires 2032-01-10 F1 · derivative.exercise_date: This option vests in equal annual installments over a three-year period measured from one year following January 11, 2022, subject to the continued service by the Reporting Person to the Issuer as of the applicable vesting date. Read SEC document |
| November 19, 2021 Filed Nov 23, 2021 00:41 UTC | Tenaya Therapeutics, Inc. TNYA · Entity 6506 | GrantStock Option (Right to Buy) · Derivative | 18,937 | $0.00 Strike: $21.65 | $0.00 |
DisclosureSEC source: 0001209191-21-066224 · doc4.xml · derivative · entry 1 Lee June · CIK 0001696493 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,937 Underlying: Common Stock · 18,937 shares Expires 2031-11-29 F1 · derivative.exercise_date: 1/36th of the shares subject to the option granted on November 19, 2021 became vested and exercisable as of December 19, 2021 and 1/36th of the shares subject to the option shall vest monthly thereafter, provided that the Reporting Person remains a service provider to the issuer on each such vest date. Read SEC document |
| September 23, 2019 Filed Sep 24, 2019 18:23 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,625 | $0.00 Strike: $11.95 | $0.00 |
DisclosureSEC source: 0000899243-19-024190 · doc4.xml · derivative · entry 6 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,617 Underlying: Common Stock · 12,625 shares Expires 2027-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that was previously adopted by the Reporting Person. F6 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| September 23, 2019 Filed Sep 24, 2019 18:23 UTC | MyoKardia, Inc. MYOK · Entity 145206 | SaleCommon Stock | 4,161 | $61.09 | $254,191.33 |
DisclosureSEC source: 0000899243-19-024190 · doc4.xml · nonDerivative · entry 5 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,153 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that was previously adopted by the Reporting Person. F5 · price: Represents the weighted average sale price of the shares sold ranging from $60.69 to $61.65 per share. Read SEC document |
| September 23, 2019 Filed Sep 24, 2019 18:23 UTC | MyoKardia, Inc. MYOK · Entity 145206 | SaleCommon Stock | 800 | $59.95 | $47,960.00 |
DisclosureSEC source: 0000899243-19-024190 · doc4.xml · nonDerivative · entry 4 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,314 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that was previously adopted by the Reporting Person. F4 · price: Represents the weighted average sale price of the shares sold ranging from $59.69 to $60.64 per share. Read SEC document |
| September 23, 2019 Filed Sep 24, 2019 18:23 UTC | MyoKardia, Inc. MYOK · Entity 145206 | SaleCommon Stock | 4,161 | $58.97 | $245,389.15 |
DisclosureSEC source: 0000899243-19-024190 · doc4.xml · nonDerivative · entry 3 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,114 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that was previously adopted by the Reporting Person. F3 · price: Represents the weighted average sale price of the shares sold ranging from $58.69 to $59.65 per share. Read SEC document |
| September 23, 2019 Filed Sep 24, 2019 18:23 UTC | MyoKardia, Inc. MYOK · Entity 145206 | SaleCommon Stock | 3,929 | $58.33 | $229,183.68 |
DisclosureSEC source: 0000899243-19-024190 · doc4.xml · nonDerivative · entry 2 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,275 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that was previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $57.69 to $58.68 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (5) to this Form 4. Read SEC document |
| September 23, 2019 Filed Sep 24, 2019 18:23 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionCommon Stock | 12,625 | $11.95 | $150,868.75 |
DisclosureSEC source: 0000899243-19-024190 · doc4.xml · nonDerivative · entry 1 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,204 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that was previously adopted by the Reporting Person. Read SEC document |
| September 19, 2019 Filed Sep 20, 2019 17:31 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,435 | $0.00 Strike: $11.95 | $0.00 |
DisclosureSEC source: 0000899243-19-024005 · doc4.xml · derivative · entry 3 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,242 Underlying: Common Stock · 5,435 shares Expires 2027-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that was previously adopted by the Reporting Person. F3 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| September 19, 2019 Filed Sep 20, 2019 17:31 UTC | MyoKardia, Inc. MYOK · Entity 145206 | SaleCommon Stock | 5,435 | $57.08 | $310,253.71 |
DisclosureSEC source: 0000899243-19-024005 · doc4.xml · nonDerivative · entry 2 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,579 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that was previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $57.00 to $57.22 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| September 19, 2019 Filed Sep 20, 2019 17:31 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionCommon Stock | 5,435 | $11.95 | $64,948.25 |
DisclosureSEC source: 0000899243-19-024005 · doc4.xml · nonDerivative · entry 1 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,014 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that was previously adopted by the Reporting Person. Read SEC document |
| August 09, 2019 Filed Aug 12, 2019 20:40 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionStock Option (Right to Buy) · Derivative | 4,565 | $0.00 Strike: $11.95 | $0.00 |
DisclosureSEC source: 0000899243-19-021602 · doc4.xml · derivative · entry 3 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 133,677 Underlying: Common Stock · 4,565 shares Expires 2027-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that was previously adopted by the Reporting Person. F3 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| August 09, 2019 Filed Aug 12, 2019 20:40 UTC | MyoKardia, Inc. MYOK · Entity 145206 | SaleCommon Stock | 4,565 | $57.00 | $260,218.70 |
DisclosureSEC source: 0000899243-19-021602 · doc4.xml · nonDerivative · entry 2 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,579 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that was previously adopted by the Reporting Person. F2 · price: Represents the weighted average sale price of the shares sold ranging from $57.00 to $57.04 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| August 09, 2019 Filed Aug 12, 2019 20:40 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionCommon Stock | 4,565 | $11.95 | $54,551.75 |
DisclosureSEC source: 0000899243-19-021602 · doc4.xml · nonDerivative · entry 1 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,144 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan that was previously adopted by the Reporting Person. Read SEC document |
| April 30, 2019 Filed Jun 3, 2019 17:48 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantCommon Stock | 401 | $40.78 | $16,353.98 |
DisclosureSEC source: 0000899243-19-015397 · doc4.xml · nonDerivative · entry 1 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,579 F1 · kind: Shares acquired pursuant to the Issuer's 2013 Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3(c). Read SEC document |
| March 14, 2019 Filed Mar 18, 2019 17:32 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionStock Option (Right to Buy) · Derivative | 1,758 | $0.00 Strike: $11.95 | $0.00 |
DisclosureSEC source: 0000899243-19-008163 · doc4.xml · derivative · entry 2 Lee June · CIK 0001696493 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 138,242 Underlying: Common Stock · 1,758 shares Expires 2027-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| March 14, 2019 Filed Mar 18, 2019 17:32 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionCommon Stock | 1,758 | $11.95 | $21,008.10 |
DisclosureSEC source: 0000899243-19-008163 · doc4.xml · nonDerivative · entry 1 Lee June · CIK 0001696493 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,178 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 25, 2019 Filed Oct 29, 2019 20:31 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,000 | $0.00 Strike: $11.95 | $0.00 |
DisclosureSEC source: 0000899243-19-026147 · doc4.xml · derivative · entry 22 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,250 Underlying: Common Stock · 3,000 shares Expires 2027-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: On February 1, 2017, the Reporting Person was granted an option to purchase 25,000 shares of Common Stock under the issuer's 2015 Equity Incentive Plan, the vesting of which was subject to various conditions (other than the passage of time and continued employment) that were not tied to the market price of the issuer's securities. On June 28, 2018, one of the conditions was deemed to be achieved, resulting in the vesting and exercisability of 6,250 of the shares underlying such option. Read SEC document |
| February 25, 2019 Filed Oct 29, 2019 20:31 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionCommon Stock | 3,000 | $11.95 | $35,850.00 |
DisclosureSEC source: 0000899243-19-026147 · doc4.xml · nonDerivative · entry 11 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 08, 2019 Filed Feb 12, 2019 16:28 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantRestricted Stock Units · Derivative | 22,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-003295 · doc4.xml · derivative · entry 2 Lee June · CIK 0001696493 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,600 Underlying: Common Stock · 22,600 shares Expires not disclosed F2 · derivative.exercise_price: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2019, so that all of the underlying shares shall be vested on January 1, 2023, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. Read SEC document |
| February 08, 2019 Filed Feb 12, 2019 16:28 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantStock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $40.11 | $0.00 |
DisclosureSEC source: 0000899243-19-003295 · doc4.xml · derivative · entry 1 Lee June · CIK 0001696493 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2029-02-07 F1 · derivative.exercise_date: The shares underlying the option vest in 48 equal monthly installments from January 1, 2019, so long as the Reporting Person continues to be an employee of the Issuer through each vesting date. This option is subject to accelerated vesting upon termination without cause upon a change of control of the Issuer. Read SEC document |
| January 07, 2019 Filed Jan 9, 2019 21:36 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Tax withholdingCommon Stock | 1,100 | $44.06 | $48,467.43 |
DisclosureSEC source: 0000899243-19-000913 · doc4.xml · nonDerivative · entry 1 Lee June · CIK 0001696493 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,420 Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 21:41 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionRestricted Stock Units · Derivative | 2,750 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-000380 · doc4.xml · derivative · entry 2 Lee June · CIK 0001696493 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,250 Underlying: Common Stock · 2,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2018, so that all of the underlying shares shall be vested on January 1, 2022, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. F2 · derivative.expiration_date: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. The shares of Common Stock underlying the RSUs vest in equal annual installments over 4 years from January 1, 2018, so that all of the underlying shares shall be vested on January 1, 2022, subject to the Reporting Person's continued employment with the Issuer through each vesting date. The RSUs are subject to accelerated vesting upon termination without cause after a change of control of the Issuer. Read SEC document |
| January 01, 2019 Filed Jan 3, 2019 21:41 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionCommon Stock | 2,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-19-000380 · doc4.xml · nonDerivative · entry 1 Lee June · CIK 0001696493 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,520 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 20:13 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $11.95 | $0.00 |
DisclosureSEC source: 0000899243-18-030319 · doc4.xml · derivative · entry 7 Lee June · CIK 0001696493 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 5,000 shares Expires 2027-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan. F6 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 20:13 UTC | MyoKardia, Inc. MYOK · Entity 145206 | SaleCommon Stock | 200 | $63.76 | $12,752.00 |
DisclosureSEC source: 0000899243-18-030319 · doc4.xml · nonDerivative · entry 6 Lee June · CIK 0001696493 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 770 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 20:13 UTC | MyoKardia, Inc. MYOK · Entity 145206 | SaleCommon Stock | 800 | $62.26 | $49,806.88 |
DisclosureSEC source: 0000899243-18-030319 · doc4.xml · nonDerivative · entry 5 Lee June · CIK 0001696493 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 970 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F5 · price: Represents the weighted average sale price of the shares sold ranging from $62.11 to $62.56 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 20:13 UTC | MyoKardia, Inc. MYOK · Entity 145206 | SaleCommon Stock | 1,200 | $61.07 | $73,285.32 |
DisclosureSEC source: 0000899243-18-030319 · doc4.xml · nonDerivative · entry 4 Lee June · CIK 0001696493 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,770 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F4 · price: Represents the weighted average sale price of the shares sold ranging from $60.89 to $61.32 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 20:13 UTC | MyoKardia, Inc. MYOK · Entity 145206 | SaleCommon Stock | 2,800 | $60.08 | $168,215.60 |
DisclosureSEC source: 0000899243-18-030319 · doc4.xml · nonDerivative · entry 3 Lee June · CIK 0001696493 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,970 F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. F3 · price: Represents the weighted average sale price of the shares sold ranging from $59.58 to $60.54 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 20:13 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionCommon Stock | 5,000 | $11.95 | $59,750.00 |
DisclosureSEC source: 0000899243-18-030319 · doc4.xml · nonDerivative · entry 2 Lee June · CIK 0001696493 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,770 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person. Read SEC document |
| December 03, 2018 Filed Oct 29, 2019 20:31 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionStock Option (Right to Buy) · Derivative | 364 | $0.00 Strike: $11.95 | $0.00 |
DisclosureSEC source: 0000899243-19-026147 · doc4.xml · derivative · entry 21 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,613 Underlying: Common Stock · 364 shares Expires 2027-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| December 03, 2018 Filed Oct 29, 2019 20:31 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionCommon Stock | 364 | $11.95 | $4,349.80 |
DisclosureSEC source: 0000899243-19-026147 · doc4.xml · nonDerivative · entry 10 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,157 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 06, 2018 Filed Oct 29, 2019 20:31 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionStock Option (Right to Buy) · Derivative | 364 | $0.00 Strike: $11.95 | $0.00 |
DisclosureSEC source: 0000899243-19-026147 · doc4.xml · derivative · entry 20 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,977 Underlying: Common Stock · 364 shares Expires 2027-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| November 06, 2018 Filed Oct 29, 2019 20:31 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionCommon Stock | 364 | $11.95 | $4,349.80 |
DisclosureSEC source: 0000899243-19-026147 · doc4.xml · nonDerivative · entry 9 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,793 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 31, 2018 Filed Dec 6, 2018 20:13 UTC | MyoKardia, Inc. MYOK · Entity 145206 | GrantCommon Stock | 344 | $42.16 | $14,503.04 |
DisclosureSEC source: 0000899243-18-030319 · doc4.xml · nonDerivative · entry 1 Lee June · CIK 0001696493 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 770 F1 · kind: Shares acquired pursuant to the Issuer's 2015 Employee Stock Purchase Plan. Read SEC document |
| October 11, 2018 Filed Oct 29, 2019 20:31 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $11.95 | $0.00 |
DisclosureSEC source: 0000899243-19-026147 · doc4.xml · derivative · entry 19 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,341 Underlying: Common Stock · 2,500 shares Expires 2027-01-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: 25% of the shares subject to the option vested and became exercisable on January 31, 2018, and the remaining shares subject to this option vest and become exercisable in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| October 11, 2018 Filed Oct 29, 2019 20:31 UTC | MyoKardia, Inc. MYOK · Entity 145206 | Exercise / conversionCommon Stock | 2,500 | $11.95 | $29,875.00 |
DisclosureSEC source: 0000899243-19-026147 · doc4.xml · nonDerivative · entry 8 Lee June · CIK 0001696493 · EVP, Chief Development Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,429 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.